Article: Sepracor Announces First Quarter 2005 Operating Results.

MARLBOROUGH, Mass., April 25 /PRNewswire-FirstCall/ -- Sepracor Inc. today announced its consolidated financial results for the first quarter of 2005. For the three months ended March 31, 2005, Sepracor's consolidated revenues were approximately $119.0 million, of which revenues from pharmaceutical product sales (XOPENEX(R) Inhalation Solution) were approximately $106.6 million. The net loss for the first quarter of 2005 was approximately $22.6 million, or $0.22 per share. These consolidated results compare with consolidated revenues of $99.5 million, of which revenues from pharmaceutical product sales (XOPENEX Inhalation Solution) were approximately $85.1 million, and ...

Related newspaper, magazine, and journal articles:

No articles like the one above were found.

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!